Zimmer Biomet (ZBH) to Release Quarterly Earnings on Thursday

Zimmer Biomet (NYSE:ZBH) is expected to be issuing its quarterly earnings data before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of $2.30 per share and revenue of $2.01 billion for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Zimmer Biomet Stock Down 1.2 %

Shares of NYSE:ZBH opened at $108.12 on Tuesday. The firm has a market capitalization of $21.52 billion, a P/E ratio of 20.55, a P/E/G ratio of 1.88 and a beta of 1.02. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. The stock has a 50 day moving average price of $107.94 and a 200-day moving average price of $108.24. Zimmer Biomet has a 52-week low of $100.67 and a 52-week high of $133.90.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.89%. The ex-dividend date was Monday, December 30th. Zimmer Biomet’s payout ratio is currently 18.25%.

Analyst Ratings Changes

Several equities research analysts have commented on ZBH shares. Stifel Nicolaus boosted their target price on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. Truist Financial increased their price objective on shares of Zimmer Biomet from $117.00 to $118.00 and gave the company a “hold” rating in a research report on Wednesday, December 18th. Wells Fargo & Company lifted their target price on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Oppenheimer cut their price target on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a report on Tuesday, October 15th. Finally, Royal Bank of Canada boosted their price objective on shares of Zimmer Biomet from $120.00 to $125.00 and gave the stock an “outperform” rating in a report on Monday, November 4th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $124.11.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.